<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812447051</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812447051</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Further Evidence of Oxymetazoline’s Safety in Otologic Surgery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Isaacson</surname><given-names>Glenn</given-names></name>
<degrees>MD, FAAP</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0194599812447051">Department of Otolaryngology–Head &amp; Neck Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania, USA Email: <email>glenn.isaacson@temple.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>147</volume>
<issue>1</issue>
<fpage>179</fpage>
<lpage>179</lpage>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>In “Oxymetazoline Ototoxicity in a Chinchilla Animal Model,”<sup><xref ref-type="bibr" rid="bibr1-0194599812447051">1</xref></sup> Drs Daniel, Akinpelu, Sahmkow, and Funnell and Mr Akach have used their established ototoxicity model to show that an over-the-counter preparation of this commonly used agent is not ototoxic when instilled in the ear canals of research animals with freshly placed tympanostomy tubes. Their elegant experiment includes positive and negative controls and examines both cochlear histology and distortion product otoacoustic emissions. It lays to rest concerns that the vasoconstrictive effect of oxymetazoline might damage hearing,<sup><xref ref-type="bibr" rid="bibr2-0194599812447051">2</xref></sup> despite the lack of harm to cochlear microstructure previously demonstrated.<sup><xref ref-type="bibr" rid="bibr3-0194599812447051">3</xref></sup></p>
<p>Currently, no medication has US Food and Drug Administration approval for perioperative application after tympanostomy tube placement. Therefore, use of any eardrop is considered off label. Ototopical drops decrease the incidence of postoperative tympanostomy tube occlusion and otorrhea compared with controls, but the effect is small; thus, only very safe preparations should be used. Given this logic and previous work from Dr Daniel’s laboratory, gentamicin, certain fluoroquinolones (moxifloxacin), and cerumenolytics (triethanolamine polypeptide) should be avoided after tube placement, as they damage the cochlea in this sensitive research model. Ciprofloxacin/dexamethasone otic suspension causes transient increases in auditory brainstem response thresholds in chinchillas when instilled for 7 days but produces no statistically significant long-term hearing loss or histologic damage.<sup><xref ref-type="bibr" rid="bibr4-0194599812447051">4</xref></sup></p>
<p>Freedom from experimental ototoxicity, favorable vasoconstrictive effect, and low cost make oxymetazoline an attractive agent for use in the operating room. We have previously reported a 10-year experience with oxymetazoline following tympanostomy tube placement.<sup><xref ref-type="bibr" rid="bibr5-0194599812447051">5</xref></sup> Postoperative audiometry and otoacoustic emissions testing showed no evidence of ototoxicity in more than 10,000 treated ears.</p>
<p>The work of Daniel et al provides further assurance to otolaryngologists who choose to use oxymetazoline solutions to optimize the results of their otologic surgery.</p>
<sec id="section1-0194599812447051">
<title>Disclosures</title>
<p><bold>Competing interests</bold>: Glenn Isaacson is a consultant on tonsillectomy products for Medtronic, Inc.</p>
<p><bold>Sponsorships</bold>: None.</p>
<p><bold>Funding source</bold>: None.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812447051">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniel</surname><given-names>SJ</given-names></name>
<name><surname>Akinpelu</surname><given-names>OV</given-names></name>
<name><surname>Sahmkow</surname><given-names>S</given-names></name>
<name><surname>Funnell</surname><given-names>WR</given-names></name>
<name><surname>Akache</surname><given-names>F</given-names></name>
</person-group>. <article-title>Oxymetazoline ototoxicity in a chinchilla animal model</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2012</year>;<volume>146</volume>:<fpage>114</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr2-0194599812447051">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seidman</surname><given-names>MD</given-names></name>
</person-group>. <article-title>Is oxymetazoline really safe for middle ear use?</article-title> <source>Laryngoscope</source>. <year>2005</year>;<volume>115</volume>:<fpage>1321</fpage>-<lpage>1323</lpage>.</citation>
</ref>
<ref id="bibr3-0194599812447051">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isaacson</surname><given-names>G</given-names></name>
<name><surname>Buttaro</surname><given-names>BA</given-names></name>
<name><surname>Mazeffa</surname><given-names>V</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Frenz</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Oxymetazoline solutions inhibit middle ear pathogens and are not ototoxic</article-title>. <source>Ann Otol Rhinol Laryngol</source>. <year>2005</year>;<volume>114</volume>:<fpage>645</fpage>-<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr4-0194599812447051">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniel</surname><given-names>SJ</given-names></name>
<name><surname>Munguia</surname><given-names>R</given-names></name>
</person-group>. <article-title>Ototoxicity of topical ciprofloxacin/dexamethasone otic suspension in a chinchilla animal model</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2008</year>;<volume>139</volume>:<fpage>840</fpage>-<lpage>845</lpage>.</citation>
</ref>
<ref id="bibr5-0194599812447051">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isaacson</surname><given-names>G</given-names></name>
</person-group>. <article-title>Six Sigma tympanostomy tube insertion: achieving the highest safety levels during residency training</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2008</year>;<volume>139</volume>:<fpage>353</fpage>-<lpage>357</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>